ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

flonoltinib

Also written as “Flonoltinib 75mg”, “Flonoltinib 100mg” and “flonoltinib 25mg”.

Its studies are mostly in Myeloproliferative Disorders · Polycythemia Vera, led by 2 companies.

Drug pageFlonoltinib: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 19, 20257 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Zenitar Biomedical Technologyits history only64 open or runningphase 3since Dec 19, 2025Nov 29, 2021Dec 30, 2026phase 1 · NCT07768111
Guizhou Bailing Group Pharmaceutical10 open or runningphase 1since Aug 12, 2021Aug 12, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Guizhou Bailing Group Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2021First study: phase 1 study in Myeloproliferative DisordersFirst studyNCT05115344

TargetBeta

“Flonoltinib Maleate (FM), a triple target inhibitor of JAK2/FLT3/CDK6, has the potential to inhibit JAK2 signaling pathway activity and treat bone marrow proliferative tumors.”study text, by rule · the study

Studies

The one study Guizhou Bailing Group Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05115344Myeloproliferative Disorders1WithdrawnDec 29, 20220

How it is read

Names in the registry

  • “Flonoltinib 75mg”, 3 entries
  • “Flonoltinib 100mg”, 2 entries
  • “flonoltinib 25mg”, 2 entries
  • “flonoltinib 50mg”, 2 entries
  • “flonoltinib 100mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.